Overview

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The Purpose of this trial is: - to determine complete response rate (CRR) after six cycles of chemotherapy - to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Treatments:
Antibodies, Monoclonal
BB 1101
Brentuximab Vedotin
Cyclophosphamide
Dacarbazine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Etoposide
Prednisone
Procarbazine